Preclinical Development of Anti-FGFR3 ADC for the Treatment of Bladder Cancer and Brain Tumor

Aimedbio Inc.

ΛIMEDBIO

ONCOLOGY	**Preclinical**	
Product Type	Antibody-Drug Conjugate (ADC)
Indication	Bladder cancer, brain tumors and other tumors
Target	FGFR3 (Fibroblast Growth Factor Receptor 3)
MoA (Mechanism of Action)	Binding to cell surface antigen → Receptor mediated endocytosis → Lysosomal degradation → Active payload release → Cell death and Bystander killing effect

Competitiveness	• First-in-Class, aFGFR3-ADC
	  - Superior cellular internalization and target degradation with high affinity.
	  - Composed of a novel antibody and payload.
	  - Demonstrates superior anti-tumor efficacy in bladder and GBM with FGFR3 WT/ alterations compared to the Standard of Care (SoC).
	  - High tolerability in NHP (non-human primate) study.
	  - Feasibility confirmed for combination therapy with ICI (Immune Checkpoint Inhibitor).

Development Stage	Preclinical
Route of Administration	Parenteral – intravenous

KDDF
Korea Drug Development Fund